Keyphrases
Cancer Patients
55%
Delirium
53%
Distress Management
47%
Interferon-α (IFN-α)
47%
Methylphenidate
47%
In Cancer
39%
Neuropsychiatric Adverse Events
37%
Patients with Cancer
31%
Hospitalization
31%
Neurobehavioral Functioning
29%
Chemotherapy
29%
Cancer Treatment
29%
Self-reported Depression
28%
Oncology
23%
Neurobehavior
23%
Patient Health Questionnaire-9 (PHQ-9)
23%
Screening Performance
23%
Advance Directives
23%
Manic Episode
23%
Brain Tumor Patients
23%
Radiological Changes
23%
Neurological Alterations
23%
Brain Dysfunction
23%
Edmonton Symptom Assessment System
23%
Psychiatric Symptomatology
23%
Psychotropic Drug Use
23%
Loss of Hope
23%
Advanced Cancer Patients
23%
Chaplaincy
23%
Naltrexone
23%
Psychiatry
23%
Depression Management
23%
AKT Inhibition
23%
AKT1
23%
Hepatitis C
23%
Cognitive Dysfunction
23%
Major Depressive Disorder
23%
Reversible Toxicities
23%
Generalized Anxiety Disorder-7 (GAD-7)
23%
Neuropsychological Tests
23%
Emergency Department
23%
Factor Correlation
23%
Cancer Outcomes
23%
Clinical Practice Guidelines
23%
Arousal
23%
Tumor
23%
Oncology Clinic
23%
Stimulant Therapy
23%
Brain Glucose Metabolism
23%
Mood Disturbance
23%
Pharmacology, Toxicology and Pharmaceutical Science
Delirium
100%
Malignant Neoplasm
96%
Interferon
71%
Side Effect
56%
Ovary Cancer
47%
Prospective Study
47%
Advanced Cancer
47%
Major Depression
41%
Chemotherapy
40%
Recurrent Disease
35%
Neoplasm
33%
Antidepressant
33%
Comorbidity
29%
Overall Survival
26%
Diseases
24%
Amnesia
23%
Receptor
23%
Mania
23%
Retrospective Study
23%
Methylphenidate
23%
Observational Study
23%
Cancer Recurrence
23%
Cancer Mortality
23%
Benzodiazepine Receptor
23%
Naltrexone
23%
Lupus Vulgaris
23%
Immunotherapy
23%
Alprazolam
23%
Psychotropic Agent
23%
Cross-Sectional Study
23%
Oropharynx Cancer
23%
Oropharynx Carcinoma
23%
Carbon 11
23%
Intracranial Tumor
23%
Hepatitis C
23%
Pulmonary Hypertension
14%
Cognitive Defect
13%
Encephalitis
11%
Brain Atrophy
11%
Psychomotor Retardation
11%
Brain Dysfunction
11%
Neurotoxicity
10%
Cancer Staging
10%
Pharmacological Activity
7%
Effusion
7%
Tracer
7%
Opiate Receptor
7%
Normal Human
7%
Pharmacokinetic
7%
Radioactive Material
7%
Neuroscience
Interferon
83%
Magnetic Resonance Imaging
57%
Cognitive Disorder
53%
Interferon Alfa
47%
Methylphenidate
47%
positron emission tomographic scan
41%
Central Nervous System
35%
Delirium
35%
Metabolic Pathway
35%
Adverse Effect
28%
Behavior (Neuroscience)
28%
Mental Disorder
28%
Psychostimulant
26%
Neurotoxicity
26%
Amnesia
23%
Major Depressive Disorder
23%
Mania
23%
Systemic Lupus Erythematosus
23%
Lupus Erythematosus
23%
AKT3
23%
Glutamate Decarboxylase
23%
Psychiatry
23%
Naltrexone
23%
Analeptic
23%
Nuclear Magnetic Resonance
23%
Drug Abuse
23%
Hepatitis C
23%
Single-Photon Emission Computed Tomography
23%
Immunotherapy
23%
Psychomotor Retardation
23%
Intracranial Tumor
23%
Executive Function
22%
AKT1
20%
Cognitive Function
17%
Prefrontal Cortex
15%
Neurotransmitter
14%
Frontal Lobe
11%
Temporal Lobe
11%
2-Deoxy-D-Glucose
11%
Receptor
11%
Tumor Necrosis Factor Alpha
11%
Interleukin 2
11%
Brain Function
11%
Dopaminergic
11%
Impulsivity
11%
Brain Metabolism
11%
Visual Perception
11%
Fluorine-18
11%
Motor Coordination
11%
Mood Disorder
11%
